UCLB Big Talks on Big Impacts

HeLP-Diabetes: From early-stage social venture to national roll-out

20 min · 18. syys 2023
jakson HeLP-Diabetes: From early-stage social venture to national roll-out kansikuva

Kuvaus

In the ninth episode of this podcast series, Ana Lemmo Charnalia, Senior Business Manager at UCLB, is in conversation with Orla O’Donnell , Divisional Manager at the UCL Div of Biosciences and former Chief Operating Officer of Health Digital CIC, a Community Interest Company incorporated in 2015 to commercialise HeLP-Diabetes. It is also an opportunity to celebrate Professor Elizabeth Murray’s life, who led in the development of HeLP-Diabetes. Join them in this discussion about their experiences and learnings from an early-stage social venture to the national roll-out of an online programme for people with type 2 diabetes.  Date of episode recording: 2023-09-05 Duration: 00:20:44 Language of episode: English Presenter: Ana Lemmo Charnalia Guests: Orla O'Donnell Producer: Nora Amin

Kommentit

0

Ole ensimmäinen kommentoija

Rekisteröidy nyt ja liity UCLB Big Talks on Big Impacts-yhteisöön!

Aloita maksutta

14 vrk ilmainen kokeilu

Kokeilun jälkeen 7,99 € / kuukausi. · Peru milloin tahansa.

  • Podimon podcastit
  • 20 kuunteluaikaa / kuukausi
  • Lataa offline-käyttöön

Kaikki jaksot

13 jaksot

jakson Professor Amit Nathwani’s journey to create a one-shot cure for haemophilia A kansikuva

Professor Amit Nathwani’s journey to create a one-shot cure for haemophilia A

To mark World Haemophilia Day, we sit down with Professor Amit Nathwani of the UCL Cancer Institute to explore his journey to commercialising the groundbreaking haemophilia A treatment, Roctavian. Host Nigel Campbell is joined by Prof Nathwani and Dr. Rick Fagan, UCLB Director of Biopharm, to explore how Amit’s work looking after patients with haemophilia in the NHS instilled a mission to develop a 'one and done' vaccine type approach to the condition. Amit’s lab to market story, working with UCLB, led to the creation of Roctavian, a one-time gene therapy used for the treatment of adults with severe haemophilia A. The therapy, which was licensed to BioMarin Pharmaceutical Inc, received marketing approval in Europe in 2022 and US FDA approval in 2023, and is now available to patients commercially.  Date of episode recording: 2024-04-10T00:00:00Z  Duration: 00:23:58  Language of episode: English  Presenter: Nigel Campbell  Guests: Prof Amit Nathwani; Dr Rick Fagan  Producer: Nora Amin Visit out website for the transcript: https://www.uclb.com/

17. huhti 202423 min
jakson Positive Impact: A new generation of business with society at heart kansikuva

Positive Impact: A new generation of business with society at heart

This episode we explore Positive Impact. UCLB is helping to create a new generation of businesses from UCL academics specifically with positive societal impact at their heart. The commercialisation process can be a long road requiring financial, legal, and practical support. Nigel Campbell meets two inventors, Buffy Price Co-founder and COO of Carbon Re, an AI and Climate Tech company spinout from UCL and Cambridge, and Professor Pete Coffey from UCL Institute of Ophthalmology and Founder of Tenpoint Therapeutics; both who are on that journey on how their inventions might improve our future world. We also talk to Dr Anne Lane, CEO of UCLB to find out how UCLB finds the bright ideas which will improve lives, and what it takes to scale to a point where they are having true impact. Date of episode recording: 2024-02-06T00:00:00Z Duration: 00:35:54 Language of episode: English Presenter: Nigel Campbell Guests: Anne Lane; Buffy Price; Prof Pete Coffey Producer: Nora Amin   For more information: https://www.uclb.com/podcasts/

12. helmi 202435 min
jakson The financial synergy between research commercialisation and the university kansikuva

The financial synergy between research commercialisation and the university

In this episode, Katy Bruce, CFO of UCL Business, and Charu Gorasia, CFO of UCL, will discuss the mutually beneficial relationship between the technology transfer office, such as UCLB, and the university. They will dive into the research income financial cycle and how the commercialisation income is distributed back into the research ecosystem. This podcast will also cover the challenges around commercialisation income, how to tackle these and what does the future hold. For more information and to access the transcript: www.uclb.com/event-category/podcast/ Date of episode recording: 2023-10-11 Duration: 00:27:04 Language of episode: english Presenter: Katy Bruce Guests: Charu Gorasia Producer: Nora Amin

23. marras 202327 min
jakson Commercialising research: the collaboration between tech transfer and investment kansikuva

Commercialising research: the collaboration between tech transfer and investment

In the tenth episode, Dr Anne Lane, CEO of UCLB and Dr Chris Hollowood, CEO of Syncona Investment Management, discussed the collaboration between their respective organisations in commercialising research. Syncona is a leading healthcare investment company focused on creating, building and scaling a portfolio of global leaders in life science; and Chris has been instrumental in the foundation and the development of its gene therapy strategy. In this podcast, Anne and Chris discussed how Syncona came about, its close relationship with UCL and UCL Business, and what attracted Syncona to invest in four UCLB companies. Chris also discussed the tech transfer ecosystem and what is next for Syncona. For more information and to access the transcript: www.uclb.com/event-category/podcast/ Date of episode recording: 2023-09-21 Duration: 00:30:11 Language of episode: English Presenter: Dr Anne Lane Guests: Dr Chris Hollowood Producer: Nora Amin

19. loka 202330 min
jakson HeLP-Diabetes: From early-stage social venture to national roll-out kansikuva

HeLP-Diabetes: From early-stage social venture to national roll-out

In the ninth episode of this podcast series, Ana Lemmo Charnalia, Senior Business Manager at UCLB, is in conversation with Orla O’Donnell , Divisional Manager at the UCL Div of Biosciences and former Chief Operating Officer of Health Digital CIC, a Community Interest Company incorporated in 2015 to commercialise HeLP-Diabetes. It is also an opportunity to celebrate Professor Elizabeth Murray’s life, who led in the development of HeLP-Diabetes. Join them in this discussion about their experiences and learnings from an early-stage social venture to the national roll-out of an online programme for people with type 2 diabetes.  Date of episode recording: 2023-09-05 Duration: 00:20:44 Language of episode: English Presenter: Ana Lemmo Charnalia Guests: Orla O'Donnell Producer: Nora Amin

18. syys 202320 min